Cerebrolysin
Cerebrolysin (neuropeptide preparation)
Not one peptide but a whole mixture of them — low-molecular-weight neuropeptides and amino acids derived from pig brain, given as a course of injections for cognition and brain recovery. It's the most heavily human-trialed compound on this site, and also the most argued-over: the trials genuinely disagree with each other.
What it is
People run it in cycles for cognition, memory, mental clarity, and recovery — lifting brain fog and sharpening focus is the most-repeated community theme, alongside mood and a sense of faster recovery. Abroad it's used clinically for stroke, traumatic brain injury, and dementia; the community use is a self-directed extension of that.
Its identity is that it isn't a single sequence at all — it's a standardized mixture meant to act like a cocktail of neurotrophic factors, the brain's own growth signals. That's why people frame it as a recovery and neuroplasticity tool rather than a daily driver: it's run as a course, then stopped, with the idea that the gains persist after the cycle ends. The honest twist that defines it: it's the rare community peptide with a large, formal clinical literature — and that literature is split down the middle.
Mechanism
The mixture is intended to mimic the action of endogenous neurotrophic factors — signaling molecules that support neuron survival, repair, and the formation of new connections (neuroplasticity). The low-molecular-weight peptides are small enough to be the proposed active fraction. Because it's a biological preparation rather than a defined single molecule, the precise mechanism is less pinned-down than a single-sequence peptide — part of why the trial results are so hard to reconcile.
Step 1 · what it is
Not one peptide — a whole mixture.
Cerebrolysin isn’t a single sequence. It’s a standardized mixture of small neuropeptides and amino acids, meant to act like a cocktail of the brain’s own growth signals.
Step 2 · how it’s run
Given as a course, then stopped.
It’s not a daily driver. People run it in blocks — a daily injection for roughly ten to twenty days — then come off, on the idea that the gains persist after the course ends.
Step 3 · the signal
It mimics neurotrophic factors.
Those small fragments are the proposed active fraction. They’re meant to imitate the body’s neurotrophic factors — the signals that keep neurons alive, repair them, and help them form new connections.
Step 4 · the effect
It nudges neurons to rebuild.
The intended result is neuroplasticity: supported neurons sprout new branches and connections. This is why it’s framed as a recovery and rebuilding tool rather than a daily supplement.
Step 5 · the honest twist
But the trials genuinely disagree.
It’s the most human-trialed compound here — and the most argued-over. Independent reviews of acute stroke found no benefit and flagged possible harm, while sponsored trials report benefit in stroke rehab, brain injury, and dementia.
Step 6 · the real risk
And a rare but real danger.
Because it’s a biological mixture, it carries a documented risk most peptides don’t: serious allergic reaction, including anaphylaxis. It’s the reason clinical instructions emphasize slow administration and watching the first doses.
The result
Most studied, most contested.
Read any efficacy claim against that independent-versus-sponsored split — and treat the allergy risk as the one that actually matters for safety.
The most human-trialed compound here — and the most contested. Independent reviews found no benefit / possible harm in acute stroke; sponsored trials report benefit. It's a biological mixture, with a rare but documented anaphylaxis risk.
Standard dose
| Common course | 5–10 mL per day, given as a daily course for ~10–20 days, then a break (proposed — pending dosing review)community |
|---|---|
| Route | Intramuscular is most-reported; intravenous (often diluted, slow) is used for higher volumes; some report subcutaneouscommunity |
| Cycle structure | Run in blocks (commonly 10-day to ~4-week courses, some 30–60 days), repeated periodically rather than taken continuouslycommunity |
| Lower / 'maintenance' | Some run smaller daily volumes (~1–5 mL) on longer cycles — lower-confidence community practicecommunity |
Pushing higher— going beyond the standard dosecommunity
Side effects & cautions
The most-reported community complaint is overstimulation — anxiety, agitation, restlessness, sometimes insomnia if dosed late — which tracks with its activating profile. Headache, dizziness, nausea, and sweating show up next, along with injection-site soreness (it's a course of daily shots). The one that matters most is uncommon but real and documented in the formal literature: anaphylaxis / serious allergic reaction. That's the reason the clinical-use instructions emphasize slow administration and watching the first doses.
Stacking
Most-reported alongside repair and other neuro peptides rather than as a stack 'base' — BPC-157 is the single most common pairing in the transcripts, with Semax and Selank and other nootropics also mentioned. The framing is cyclical: run the Cerebrolysin course, support it, then come off — not a permanent daily stack.
Evidence & sources
The most human-trialed compound on this site — and the most genuinely contested. Independent trials and the Cochrane review of acute ischemic stroke found no benefit on death or dependency and flagged a possible harm signal, while manufacturer-sponsored trials and meta-analyses report benefit in stroke rehab, TBI, and dementia. Read any efficacy claim against that independent-vs-sponsored split. It's also a biological mixture, not a defined single peptide, and carries a rare but documented anaphylaxis risk.
- Ziganshina LE et al. (2020)ReviewCerebrolysin for acute ischaemic stroke (Cochrane review)Cochrane Database Syst Rev — independent; no benefit, possible harmPMID 32662068 ↗
- Heiss WD et al. (2012)Human RCTCerebrolysin in patients with acute ischemic stroke in Asia (CASTA)Stroke — RCT, neutral on primary endpointPMID 22282884 ↗
- Muresanu DF et al. (2016)Human RCTCerebrolysin and recovery after stroke (CARS): a randomized controlled trialStroke — sponsored; positive on post-stroke rehabPMID 26564102 ↗
- Gauthier S et al. (2015)Human RCTCerebrolysin in mild-to-moderate Alzheimer's diseaseDement Geriatr Cogn Disord — dementia RCTPMID 25832905 ↗
- Trimmel H et al. (2024)Human studyAnaphylaxis associated with Cerebrolysin (case report)Documents the rare but real serious allergic-reaction riskPMID 39055722 ↗